Patents by Inventor Jonathan Dante LOW
Jonathan Dante LOW has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220289724Abstract: Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.Type: ApplicationFiled: August 3, 2020Publication date: September 15, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Paul BOURBEAU, Matthew Richard KALLER, Jonathan Dante LOW, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Liping H. PETTUS, Mary Catherine WALTON, Qiufen May XUE, John Gordon ALLEN
-
Publication number: 20220106293Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 14, 2021Publication date: April 7, 2022Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
-
Publication number: 20220073504Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 20, 2019Publication date: March 10, 2022Applicant: AMGEN INC.Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JAMES ALEXANDER BROWN, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, QINGYIAN LIU, JONATHAN DANTE LOW, VU MA, LIPING H PETTUS, MARY CATHERINE WALTON, ANA ELENA MINATTI, MATTHEW PAUL BOURBEAU, LEI JIA, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
-
Patent number: 11236069Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: GrantFiled: December 20, 2019Date of Patent: February 1, 2022Assignee: AMGEN INC.Inventors: Nuria A. Tamayo, Abhisek Banerjee, Jian Jeffrey Chen, Jonathan Dante Low, Ana Elena Minatti, Matthew Paul Bourbeau
-
Patent number: 10988485Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: May 9, 2019Date of Patent: April 27, 2021Assignee: Amgen Inc.Inventors: Ana Elena Minatti, Jonathan Dante Low, Ryan Paul Wurz, Brian Alan Lanman, Victor J. Cee, Michael D. Bartberger, Margaret Chu-Moyer
-
Publication number: 20200239441Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.Type: ApplicationFiled: December 20, 2019Publication date: July 30, 2020Applicant: AMGEN INC.Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
-
Publication number: 20190345169Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: May 9, 2019Publication date: November 14, 2019Inventors: Ana Elena MINATTI, Jonathan Dante LOW, Ryan Paul WURZ, Brian Alan LANMAN, Victor J. CEE, Michael D. BARTBERGER, Margaret CHU-MOYER
-
Publication number: 20140011796Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: September 12, 2013Publication date: January 9, 2014Applicant: AMGEN INC.Inventors: Michael David BARTBERGER, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason Duquette, John Eksterwicz, Benjamin Fisher, Brian Matthew Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael William Gribble, Dann James Gustin, Julie Anne Heath, Xin Huang, Xianyun Jiao, Michael Johnson, Frank Kayser, David John Kopecky, Sujen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan Dante Low, Brian Stuart Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin McMinn, Julio Cesar Medina, Jeffrey Thomas Mihalic, Steven Howard Olson, Yosup Rew, Philip Marley Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
-
Publication number: 20110319378Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.Type: ApplicationFiled: June 3, 2011Publication date: December 29, 2011Applicant: AMGEN INC.Inventors: Michael David BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian Matthew FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael GRIBBLE, JR., Darin James GUSTIN, Julie Anne HEATH, Xin HUANG, Xianyun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, Sujen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan Dante LOW, Brian Stuart LUCAS, Zhihua MA, Lawrence McGEE, Joel McINTOSH, Dustin McMINN, Julio Cesar MEDINA, Jeffrey Thomas MIHALIC, Steven Howard Olson, Yosup REW, Philip Marley ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU